YWHAE重排高级别子宫内膜间质肉瘤:两中心病例系列及化疗反应
本研究回顾性分析两中心7例YWHAE重排高级别子宫内膜间质肉瘤(HG-ESS)患者的化疗反应。6例接受蒽环类为基础化疗,其中2例达完全影像学缓解;1例接受吉西他滨联合多西他赛达部分缓解。中位随访27个月,提示蒽环类化疗对该转移性肿瘤有效。
要点
- YWHAE重排HG-ESS罕见,携带t(10;17)(q22;p13)致YWHAE-NUTM2A/B融合。
- 6例接受蒽环类化疗,2例达完全影像学缓解;1例吉西他滨联合多西他赛达部分缓解。
- 转移性患者诊断后可见 prolonged 疾病控制,强调需对子宫间叶恶性肿瘤行分子检测。
核心结论
- 转移性YWHAE重排HG-ESS诊断后可见 prolonged 疾病控制,蒽环类为基础治疗有显著反应。
- 强调需对子宫间叶恶性肿瘤进行适当分子检测,提示化疗是转移性YWHAE重排HG-ESS的有效治疗选择。
研究设计与样本
- 回顾性识别在两中心因转移性疾病接受治疗的YWHAE重排HG-ESS患者。
- 全部病例经细胞遗传学或荧光原位杂交确认重排,并结合组织病理学诊断。
- 共识别7例符合纳入标准的YWHAE重排HG-ESS患者。
主要发现
- 诊断时中位年龄45岁(范围42-47)。
- 全部患者接受全子宫切除及双侧输卵管卵巢切除。
- 诊断时FIGO分期:4例IVB,IIIB、II、I期各1例。
- 队列中位随访27个月(范围6-123)。
- 6例接受蒽环类为基础化疗,其中2例达完全影像学缓解;1例接受吉西他滨联合多西他赛达部分缓解;3例死于转移性疾病者自初诊生存分别为33、100、123个月。
临床怎么用
- 作者认为,对转移性YWHAE重排HG-ESS,化疗是有效的治疗选择。
- 作者强调需对子宫间叶恶性肿瘤进行适当分子检测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: YWHAE-rearranged high-grade endometrial stromal sarcoma (HG-ESS) is a rare, recently defined uterine sarcoma harboring t(10;17)(q22;p13) resulting in YWHAE-NUTM2A/B fusion. Chemotherapy sensitivity of metastatic YWHAE-rearranged HG-ESS is unknown. We reviewed the response to chemotherapy in women with YWHAE-rearranged HG-ESS to provide guidance for clinical management. METHODS: We retrospectively identified patients diagnosed with YWHAE-rearranged HG-ESS who received treatment for metastatic disease at our institutions. Cytogenetics or fluorescence in situ hybridization were performed in all cases to confirm rearrangement and, in conjunction with histopathology, a diagnosis of YWHAE-rearranged HG-ESS. Patient demographics, tumor histology, surgical procedures, radiation therapy, chemotherapy and treatment responses were collected. RESULTS: Seven patients were identified with YWHAE-rearranged HG-ESS and met criteria for inclusion in this study. The median age at diagnosis was 45 (range 42-47). All patients had undergone hysterectomy with bilateral salpingo-oophorectomy. FIGO stage at diagnosis was IVB in four patients and a single patient each at stage IIIB, II or I. Median follow-up for the cohort was 27months (range 6-123). Six patients received anthracycline-based chemotherapy, with two of six achieving a complete radiologic response. One patient received gemcitabine and docetaxel, resulting in a partial response. For three patients who died from metastatic disease, survival from initial diagnosis was 33, 100 and 123months. CONCLUSIONS: For metastatic YWHAE-rearranged HG-ESS, prolonged disease control following diagnosis was seen, with notable responses to anthracycline-based therapy. This emphasizes the need for appropriate molecular testing of uterine mesenchymal malignancies and suggests that chemotherapy is an effective treatment option for metastatic YWHAE-rearranged HG-ESS.
引用
- Hemming ML, Wagner AJ, Nucci MR, et al. YWHAE-rearranged high-grade endometrial stromal sarcoma: Two-center case series and response to chemotherapy. Gynecol Oncol. 2017. PMID: 28390819. doi:10.1016/j.ygyno.2017.03.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。